Phospho-GATA4 (S262) Antibody

What is GATA4 and what is the significance of phosphorylation at serine 262?

GATA4 is a critical transcription factor that belongs to the GATA family of zinc-finger transcription factors. It binds to the consensus sequence 5'-AGATAG-3' and plays a key role in cardiac development and function . GATA4 is involved in regulating genes essential for embryogenesis and myocardial differentiation . The phosphorylation of GATA4 at serine 262 (S262) represents a specific post-translational modification that affects the protein's function. This phosphorylation is an important regulatory mechanism that can alter GATA4's DNA binding capacity, transcriptional activity, and its role in cardiac development and hypertrophic responses . Unlike phosphorylation at S105, which has been more extensively characterized in relation to MAPK pathways and cardiac hypertrophy, S262 phosphorylation represents a distinct regulatory mechanism that researchers can specifically detect and study using phospho-specific antibodies.

How does Phospho-GATA4 (S262) Antibody differ from other GATA4 antibodies?

Phospho-GATA4 (S262) Antibody is designed with unique specificity to detect GATA4 only when phosphorylated at serine 262, distinguishing it from other GATA4 antibodies in the following ways:

• Target specificity: This antibody specifically recognizes the phosphorylated form of GATA4 at serine 262, whereas standard GATA4 antibodies detect the protein regardless of its phosphorylation state .

• Detection capability: The antibody detects "endogenous levels of GATA4 only when phosphorylated at Serine 262," allowing researchers to specifically monitor this post-translational modification .

• Immunogen design: These antibodies are typically generated using synthesized peptides derived from human GATA4 specifically around the phosphorylation site of Ser262, ensuring their phospho-specificity .

• Purification method: The antibody undergoes rigorous purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns, enhancing its specificity for the phosphorylated epitope .

This specificity allows researchers to distinguish between phosphorylated and non-phosphorylated forms of GATA4, which is crucial for studying signaling pathways that regulate GATA4 activity through this specific phosphorylation site.

What experimental applications is the Phospho-GATA4 (S262) Antibody validated for?

Phospho-GATA4 (S262) Antibody has been validated for multiple experimental applications, providing researchers with versatile options for detecting this specific phosphorylation:

The antibody's validation across these multiple techniques makes it a versatile tool for examining GATA4 phosphorylation in diverse experimental contexts, from protein quantification to spatial localization within cells and tissues .

What is the recommended protocol for using Phospho-GATA4 (S262) Antibody in Western blotting experiments?

For optimal Western blotting results with Phospho-GATA4 (S262) Antibody, researchers should follow this methodological approach:

• Sample preparation:

  • Extract proteins from tissues or cells under conditions that preserve phosphorylation (use phosphatase inhibitors in lysis buffers)

  • Quantify protein concentration and load equal amounts (typically 20-50 μg) per lane

• Gel electrophoresis and transfer:

  • Separate proteins using 10-12% SDS-PAGE (GATA4 has a molecular weight of approximately 44 kDa)

  • Transfer to PVDF or nitrocellulose membrane using standard protocols

• Blocking and antibody incubation:

  • Block membrane with 5% BSA in TBST (not milk, which contains phosphatases)

  • Incubate with Phospho-GATA4 (S262) Antibody at dilutions between 1:500-1:2000 in blocking buffer overnight at 4°C

  • Wash 3-5 times with TBST

• Detection:

  • Incubate with appropriate HRP-conjugated secondary antibody (anti-rabbit IgG, typically 1:5000-1:10000)

  • Develop using enhanced chemiluminescence (ECL) substrate

  • Image using film or digital imaging system

• Controls and validation:

  • Include a positive control (tissue/cells known to express phosphorylated GATA4)

  • Consider including a lambda phosphatase-treated sample as a negative control to confirm phospho-specificity

  • For normalization, strip and reprobe with antibodies against total GATA4 or loading controls like GAPDH/β-actin

This protocol emphasizes preservation of phosphorylation status throughout the procedure, which is critical for accurate detection of this post-translational modification .

How can researchers validate the specificity of Phospho-GATA4 (S262) Antibody in their experimental system?

Validating antibody specificity is crucial for ensuring reliable results. For Phospho-GATA4 (S262) Antibody, researchers should consider these validation approaches:

• Phosphatase treatment control:

  • Treat duplicate samples with lambda phosphatase before Western blotting

  • The signal should disappear in phosphatase-treated samples if the antibody is specific

• Stimulation experiments:

  • Treat cells with stimuli known to induce GATA4 phosphorylation (similar to how S105 phosphorylation increases upon pressure overload stimulation)

  • Compare phosphorylation levels before and after stimulation

• Knockout/knockdown validation:

  • Use GATA4 knockout or knockdown samples as negative controls

  • No signal should be detected in these samples

• Peptide competition assay:

  • Pre-incubate the antibody with the immunizing phospho-peptide

  • This should block specific binding and eliminate the signal

• Cross-reactivity assessment:

  • Test the antibody in multiple species (human, mouse, rat) to confirm the predicted reactivity

  • Check for potential cross-reactivity with other GATA family members

• Correlation with functional outcomes:

  • Correlate phosphorylation detection with known functional consequences of GATA4 phosphorylation, such as DNA binding activity changes

What are the optimal storage and handling conditions for maintaining Phospho-GATA4 (S262) Antibody activity?

To preserve antibody functionality and specificity, proper storage and handling of Phospho-GATA4 (S262) Antibody is essential:

• Storage temperature:

  • Store at -20°C for long-term preservation

  • Avoid storing at 4°C for extended periods

• Aliquoting recommendations:

  • Upon receipt, prepare small single-use aliquots to minimize freeze-thaw cycles

  • Most products are supplied in 50% glycerol to allow for aliquoting without freezing solid

• Buffer composition:

  • Typically supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

  • This formulation helps maintain antibody stability

• Freeze-thaw considerations:

  • Avoid repeated freeze-thaw cycles as they can degrade antibody quality

  • Limit to no more than 5 cycles throughout the antibody's usage period

• Working dilution preparation:

  • Prepare fresh working dilutions on the day of experiment

  • Do not store diluted antibody for extended periods

• Contamination prevention:

  • Use sterile technique when handling the antibody stock

  • Sodium azide in the storage buffer prevents microbial growth but is incompatible with HRP-based detection systems

Following these storage and handling guidelines will help maintain antibody performance throughout its expected shelf life of approximately one year from the date of receipt .

How can Phospho-GATA4 (S262) Antibody be used to investigate cardiac hypertrophy mechanisms?

Cardiac hypertrophy research can be significantly advanced using Phospho-GATA4 (S262) Antibody through these methodological approaches:

• Hypertrophic stimulation time-course studies:

  • Treat cardiomyocytes with hypertrophic stimuli (PE, angiotensin II, ET-1)

  • Monitor S262 phosphorylation at different time points using Western blotting

  • Compare with S105 phosphorylation patterns, which are known to increase during hypertrophic responses

• In vivo cardiac hypertrophy models:

  • Utilize pressure overload models (aortic banding, similar to studies on S105)

  • Analyze myocardial tissue sections using immunohistochemistry to detect spatial distribution of phosphorylated GATA4

  • Correlate phosphorylation levels with hypertrophic markers (ANF, BNP) and cardiomyocyte size

• Signaling pathway delineation:

  • Use specific kinase inhibitors to identify the upstream regulators of S262 phosphorylation

  • Compare with known MAPK pathways that regulate S105 phosphorylation

  • Investigate potential crosstalk between different GATA4 phosphorylation sites

• Functional consequences assessment:

  • Combine with DNA binding assays (EMSA, ChIP) to determine how S262 phosphorylation affects GATA4 binding to cardiac gene promoters

  • Assess if S262 phosphorylation alters GATA4 transcriptional activity through reporter gene assays

  • Investigate if S262 phosphorylation affects protein-protein interactions with cardiac cofactors like NKX2-5

• Multimerization analysis:

  • Investigate whether S262 phosphorylation affects GATA4 multimerization, which has been shown to regulate transcriptional activity

  • Use co-immunoprecipitation with total GATA4 antibodies followed by detection with Phospho-GATA4 (S262) Antibody

These approaches can provide comprehensive insights into how S262 phosphorylation contributes to GATA4 function in cardiac hypertrophy, potentially revealing novel therapeutic targets for heart disease .

What is the relationship between different GATA4 phosphorylation sites, and how can they be comparatively studied?

GATA4 contains multiple phosphorylation sites that likely work in concert to regulate its activity. Researchers can use the following approaches to study the interrelationships between these sites:

• Comparative phosphorylation profiling:

  • Use site-specific antibodies (anti-pS105 and anti-pS262) to monitor multiple phosphorylation sites simultaneously

  • Determine if phosphorylation events occur sequentially or independently

  • Examine whether different stimuli induce phosphorylation at specific sites preferentially

• Functional consequences comparison:

  • S105 phosphorylation by ERK1/2 and p38 MAPK increases DNA binding activity and transcriptional potency

  • Design experiments to determine if S262 phosphorylation produces similar or distinct functional outcomes

  • Use reporter gene assays with GATA-responsive promoters to compare transcriptional effects

• Kinase identification and pathway mapping:

  • S105 is phosphorylated by ERK1/2 and p38 MAPK downstream of neuroendocrine stress signaling

  • Employ kinase inhibitors and activation experiments to identify kinases responsible for S262 phosphorylation

  • Map the signaling pathways leading to each phosphorylation site

• Mutational analysis strategies:

  • Create phosphomimetic (S→D/E) and phosphodeficient (S→A) mutations at each site

  • Generate double mutants to assess interplay between phosphorylation sites

  • Compare with the phenotype of Gata4-S105A knock-in mice that showed reduced hypertrophic response

• Temporal dynamics analysis:

  • Examine the timing of phosphorylation at different sites during cardiac development or hypertrophic responses

  • Determine if one phosphorylation event primes for or inhibits others

This comparative approach will provide a more complete understanding of how multiple phosphorylation events coordinate to regulate GATA4 activity in different physiological and pathological contexts .

What methodological approaches can be used to identify upstream kinases responsible for GATA4 S262 phosphorylation?

Identifying the kinases that phosphorylate GATA4 at S262 requires a systematic approach combining multiple techniques:

• In silico kinase prediction:

  • Analyze the amino acid sequence surrounding S262 using kinase prediction algorithms

  • Compare with known consensus sequences for serine/threonine kinases

  • Identify candidate kinases based on sequence context and cellular localization

• Kinase inhibitor screening:

  • Treat cardiomyocytes or relevant cell lines with a panel of kinase inhibitors

  • Monitor S262 phosphorylation by Western blotting with Phospho-GATA4 (S262) Antibody

  • Compare results with known effects on S105, which is phosphorylated by ERK1/2 and p38 MAPK

• Direct in vitro kinase assays:

  • Express recombinant GATA4 protein

  • Conduct in vitro kinase reactions with purified candidate kinases

  • Detect phosphorylation using Phospho-GATA4 (S262) Antibody or radioisotope labeling

• Genetic manipulation approaches:

  • Overexpress constitutively active or dominant negative kinase mutants

  • Use siRNA/shRNA to knock down candidate kinases

  • Employ CRISPR-Cas9 to generate kinase knockout cell lines

  • Analyze effects on S262 phosphorylation in response to appropriate stimuli

• Proximity-based proteomic approaches:

  • Employ BioID or APEX2 proximity labeling with GATA4 as bait

  • Identify kinases that physically interact with GATA4

  • Validate candidates through co-immunoprecipitation experiments

• Phosphoproteomics integration:

  • Conduct phosphoproteomic analysis before and after stimulation

  • Monitor changes in GATA4 phosphorylation at S262 alongside known kinase substrates

  • Infer potential kinase activity based on phosphorylation patterns

These complementary approaches can reveal the kinases responsible for S262 phosphorylation, which may differ from or overlap with those that phosphorylate S105 (ERK1/2 and p38 MAPK), potentially uncovering new regulatory mechanisms for GATA4 activity .

How can researchers troubleshoot common issues when using Phospho-GATA4 (S262) Antibody in experimental procedures?

When working with Phospho-GATA4 (S262) Antibody, researchers may encounter several challenges. Here are methodological solutions for common issues:

• Weak or absent signal in Western blotting:

  • Ensure phosphorylation preservation by using fresh phosphatase inhibitors in all buffers

  • Increase antibody concentration (try 1:500 instead of 1:2000)

  • Extend primary antibody incubation time to overnight at 4°C

  • Enrich for nuclear proteins since GATA4 is a nuclear transcription factor

  • Use enhanced chemiluminescence substrates with higher sensitivity

  • Consider sample enrichment techniques like immunoprecipitation before Western blotting

• High background or non-specific bands:

  • Increase blocking time (1-2 hours at room temperature)

  • Use 5% BSA instead of milk for blocking and antibody dilution

  • Increase washing steps (5-6 times for 10 minutes each)

  • Try a more dilute antibody solution (1:1000-1:2000)

  • Optimize secondary antibody concentration

  • Pre-adsorb antibody with non-specific proteins

• Inconsistent results between experiments:

  • Standardize tissue/cell lysis protocol to ensure consistent phosphorylation preservation

  • Use positive controls with known phosphorylation status

  • Include phosphatase-treated samples as negative controls

  • Normalize loading with appropriate housekeeping proteins

  • Maintain consistent experimental conditions (stimulation time, intensity)

• Poor immunofluorescence staining:

  • Optimize fixation method (4% paraformaldehyde is typically recommended)

  • Try antigen retrieval methods if using fixed tissue sections

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use a more concentrated antibody solution (1:200)

  • Include detergent (0.1-0.3% Triton X-100) in blocking buffer for better permeabilization

  • Ensure nuclear visualization with DAPI counterstaining

• Antibody degradation issues:

  • Prepare small single-use aliquots to minimize freeze-thaw cycles

  • Store at -20°C in recommended buffer conditions

  • Check for signs of microbial contamination before use

  • Validate antibody performance periodically with positive control samples

These troubleshooting approaches address the specific challenges associated with detecting phosphorylated transcription factors like GATA4, which may be present at relatively low abundance and require careful preservation of post-translational modifications .

How can Phospho-GATA4 (S262) Antibody contribute to understanding the role of GATA4 in diseases beyond cardiac hypertrophy?

Phospho-GATA4 (S262) Antibody can facilitate research into GATA4's role in multiple disease contexts through these methodological approaches:

• Congenital heart defects (CHDs):

  • Analyze phosphorylation patterns in tissue samples from CHD patients

  • Correlate S262 phosphorylation levels with specific cardiac malformations

  • GATA4 mutations are associated with cardiac septal defects, making phosphorylation status potentially relevant to disease mechanisms

• Cancer research applications:

  • Examine S262 phosphorylation in cancers where GATA4 acts as an oncogene or tumor suppressor

  • Compare phosphorylation levels between normal and malignant tissues

  • Investigate whether S262 phosphorylation correlates with cancer progression or metastasis

• Developmental biology studies:

  • Track S262 phosphorylation during embryonic development using immunohistochemistry

  • Determine if phosphorylation status changes during key developmental transitions

  • Compare with other phosphorylation sites to establish a comprehensive regulatory model

• Reproductive system disorders:

  • GATA4 is required for testicular development

  • Study S262 phosphorylation in models of reproductive system disorders

  • Compare phosphorylation patterns in normal and pathological gonadal tissues

• Metabolic disease connections:

  • Investigate S262 phosphorylation in metabolic tissues where GATA4 may play a role

  • Examine whether obesity, diabetes, or other metabolic conditions alter GATA4 phosphorylation

  • Explore potential links to sphingolipid signaling, which GATA4 has been implicated in regulating

• Regenerative medicine applications:

  • Monitor S262 phosphorylation during cardiac regeneration or repair processes

  • Determine if modulating phosphorylation could enhance regenerative capacity

  • Study phosphorylation dynamics during stem cell differentiation into cardiomyocytes

These diverse applications highlight how Phospho-GATA4 (S262) Antibody can advance understanding of GATA4 regulation across multiple disease contexts beyond the established role in cardiac hypertrophy .

What novel methodological approaches can enhance the utility of Phospho-GATA4 (S262) Antibody in research?

Emerging technologies can significantly extend the research applications of Phospho-GATA4 (S262) Antibody:

• Single-cell phosphoprotein analysis:

  • Adapt phospho-flow cytometry protocols for detecting S262 phosphorylation at the single-cell level

  • Combine with other markers to identify specific cell populations with active GATA4 signaling

  • This approach would reveal heterogeneity in GATA4 phosphorylation within tissues

• Multiplexed phosphorylation detection:

  • Develop multiplexed immunofluorescence protocols to simultaneously detect multiple GATA4 phosphorylation sites

  • Use spectral unmixing and multi-epitope ligand cartography (MELC) techniques

  • This would enable comprehensive mapping of GATA4 phosphorylation status

• Live-cell phosphorylation monitoring:

  • Generate phospho-specific intracellular antibody fragments (intrabodies) based on Phospho-GATA4 (S262) Antibody

  • Create FRET-based biosensors for real-time monitoring of S262 phosphorylation

  • This would allow dynamic tracking of phosphorylation events in living cells

• ChIP-seq applications:

  • Adapt Phospho-GATA4 (S262) Antibody for chromatin immunoprecipitation sequencing

  • Compare genome-wide binding patterns of phosphorylated versus non-phosphorylated GATA4

  • This would reveal how S262 phosphorylation affects DNA binding site selection across the genome

• Spatial transcriptomics integration:

  • Combine immunohistochemistry using Phospho-GATA4 (S262) Antibody with spatial transcriptomics

  • Correlate phosphorylation status with localized gene expression patterns

  • This approach would reveal functional consequences of phosphorylation in tissue context

• Advanced proximity labeling:

  • Use Phospho-GATA4 (S262) Antibody in conjunction with proximity labeling techniques (BioID, APEX)

  • Identify phosphorylation-specific protein interaction partners

  • This could uncover how phosphorylation alters GATA4's interactome

These innovative approaches extend beyond traditional antibody applications, leveraging cutting-edge technologies to provide deeper insights into the dynamic regulation and function of GATA4 phosphorylation at S262.

How should researchers design experiments to compare phosphorylation at different GATA4 sites (e.g., S105 vs. S262)?

Designing rigorous comparative studies of GATA4 phosphorylation sites requires careful methodological planning:

• Parallel detection strategy:

  • Process identical samples in parallel with phospho-specific antibodies against S105 and S262

  • Ensure equivalent antibody performance by testing sensitivity and specificity with phosphopeptide competition

  • Include total GATA4 detection for normalization purposes

• Stimulus-response experimental design:

  • Test multiple stimuli known to activate different signaling pathways:

    • PE/angiotensin II (MAPK pathway – known to increase S105 phosphorylation)

    • Growth factors (e.g., hepatocyte growth factor)

    • Mechanical stretch

    • Cytokines

  • Collect samples at multiple time points (5 min, 15 min, 30 min, 1 hr, 3 hr, 24 hr)

  • This approach will reveal differential regulation of phosphorylation sites

• Kinase manipulation framework:

  • Apply specific kinase inhibitors:

    • MEK1 inhibitors (U0126, PD98059) – blocks ERK1/2 activation that phosphorylates S105

    • p38 MAPK inhibitors (SB203580)

    • Other pathway-specific inhibitors

  • Use constitutively active kinase constructs to drive phosphorylation

  • This will identify kinases specific to each phosphorylation site

• Comparative site-directed mutagenesis:

  • Generate the following GATA4 mutants:

    • S105A (phospho-deficient at S105)

    • S262A (phospho-deficient at S262)

    • S105A/S262A (double mutant)

    • S105D and S262D (phosphomimetics)

  • Assess functional consequences of each mutation individually and in combination

  • Compare results with the documented phenotypes of Gata4-S105A knock-in mice

• Integrated multi-omics approach:

  • Combine results from:

    • Phosphoproteomics to identify all phosphorylation sites

    • ChIP-seq to map genomic binding sites

    • RNA-seq to measure transcriptional effects

  • This comprehensive approach will establish the functional relationship between different phosphorylation sites